The Council of Medical Specialty Societies (CMSS) and the Coalition for Health AI (CHAI) have partnered to progress responsible and ethical uses of artificial intelligence (AI) in health care settings. The two organizations together will develop continuing medical education programs around AI knowledge and technologies for medical specialties.
“Physicians turn to their specialty societies as trusted sources of guidance on emerging challenges, including the responsible integration of AI into healthcare,” stated Helen Burstin, MD, MPH, the CEO of CMSS. “Our partnership with CHAI will empower our member societies to deliver tailored, high-quality educational resources that meet the evolving needs of their physician members.”
“I’m thrilled to be working with CMSS in this new formal partnership to help specialty societies utilize AI and the many benefits these new technologies bring, at a scale and level of specificity we have never been able to achieve before,” said Brian Anderson, MD, the President and CEO of CHAI. “Together, we’re leading the development of AI curricula tailored to the needs of the many different medical specialties to elevate patient safety and quality, and ultimately improve health outcomes for all.”
The CMSS is a coalition of more than 50 medical specialty societies that represents over 800,000 physicians. The organization serves the collective voice of specialty societies’ physicians and patients by driving toward meaningful change for the future of health care.
The CHAI, a nonprofit organization started by clinicians to advocate for and advance the responsible use of AI in health care, aims to create the broadest possible consensus for AI use in health care to ensure that the tools and technologies used are safe, secure, and able to be trusted. The organization now consists of over 4,000 health systems, patient advocacy groups, academia, and a range of industry groups, with no limits on their membership.
ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.
Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results of a recent study published in JAAD International.
“This type of cancer, which is a result of mutations of the most common cell type in the top layer of the skin, is strongly linked to accumulated [ultraviolet] radiation over time. It develops in sun-exposed areas, often on skin already showing signs of sun damage, with rough scaly patches, uneven pigmentation, and decreased elasticity,” stated lead researcher Sam Polesie, MD, PhD, Associate Professor of Dermatology and Venereology at the University of Gothenburg and Practicing Dermatologist at Sahlgrenska University Hospital, both in Gothenburg, Sweden.